Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses
- Erika J. Lampert
- , Ashley Cimino-Mathews
- , Joo Sang Lee
- , Jayakumar Nair
- , Min Jung Lee
- , Akira Yuno
- , Daniel An
- , Jane B. Trepel
- , Eytan Ruppin
- , Jung Min Lee
Research output: Contribution to journal › Article › peer-review
19
Link opens in a new tab
Scopus
citations